| Literature DB >> 36105148 |
Qingqing Du1, Fen Pan1, Chun Wang1, Fangyuan Yu1, Yingying Shi1, Wenxin Liu1, Zhi Li2, Ping He3, Dingding Han1, Hong Zhang1.
Abstract
Objectives: Although hypervirulent Klebsiella pneumoniae (hvKp) is an increasing public health problem, there remains limited epidemiological information regarding hvKp infections in children. Here, we conducted a clinical, molecular and phenotypic surveillance of hvKp strains in a pediatric population.Entities:
Keywords: Klebsiella pneumoniae; carbapenem-resistant; child; hypervirulence; infection; surveillance
Mesh:
Substances:
Year: 2022 PMID: 36105148 PMCID: PMC9464974 DOI: 10.3389/fcimb.2022.984180
Source DB: PubMed Journal: Front Cell Infect Microbiol ISSN: 2235-2988 Impact factor: 6.073
Figure 1Flowchart for screening hypervirulent K. pneumoniae (hvKp) in this study. HgKp, hypervirulence genes-positive K. pneumoniae; hgKp-Lv, hgKp-low virulence.
Figure 2Features of hypervirulent K pneumoniae strains. (A) Distribution of hypervirulence genes among hgKp isolates (n = 83). (B) Hypervirulence genes, hypervirulence phenotypes, plasmid types, and resistance genes of hvKp isolates (n = 27) with various capsule K serotypes and sequence types. Phylogenetic relationships were analyzed by Phyloviz 2.0 software using hierarchical clustering based on the genetic distance of sequence types. HM, hypermucoviscous phenotype; SK, serum resistance; SP, siderophore production; 24h-GML, 24-hour lethality in G mellonella infection model. Resistance determinants without text meant no other genes carried except bla SHV (intrinsic resistance for K pneumoniae). (C) Antimicrobial resistance rates of hvKp (n = 27) and hgKp-Lv (n = 56). AMP, ampicillin; CXM, cefuroxime; CRO, ceftriaxone; CZO, cefazolin; CTX, cefotaxime; GEN, gentamicin; FEP, cefepime; CAZ, ceftazidime; SXT, trimethoprim-sulfamethoxazole; FOX, cefoxitin; SAM, ampicillin-sulbactam; TZP, piperacillin-tazobactam; AMC, amoxicillin-clavulanic acid; SCF, cefoperazone-sulbactam; FOS, fosfomycin; LVX, levofloxacin; IPM, imipenem; MEM, meropenem; ETP, ertapenem; AMK, amikacin; POL, polymyxin B; TGC, tigecycline. Antimicrobial agents labelled with the same color were grouped into a single antimicrobial category: AMP, Penicillins; CXM/CRO/CZO/CTX/FEP/CAZ/FOX, Cephems; GEN/AMK, Aminoglycosides; SXT, Folate pathway inhibitors; SAM/AMC/SCF/TZP, β lactam combination agents; FOS, Fosfomycins; IPM/ETP/MEM, Carbapenems; LXT, Antipseudomonal fluoroquinolones; TGC, Glycylcyclines; POL, Polymyxins.
Comparison of characteristics between hypervirulent K. pneumoniae (hvKp) isolates (n = 27) and hypervirulence genes-positive K. pneumoniae-low virulence (hgKp-Lv) isolates (n = 56).
| HvKp (n = 27) | HgKp-Lv (n = 56) |
| |
|---|---|---|---|
|
| |||
| Age (yrs) (median [IQR] | 3.95 (0.25 - 9.86) | 0.12 (0.05 - 0.82) | 0.0001* (Z = 3.8443) |
| Male sex (n [%] | 18 (66.7) | 32 (57.1) | 0.4062 (χ2 = 0.6899) |
|
| |||
| White blood cell count (×109/L) | 8.03 (5.76 - 13.65) | 11.41 (7.86 - 18.72) | 0.0447* (Z = -2.0073) |
| Neutrophil count (%) | 51.40 (33.50 - 64.70) | 48.70 (31.75 - 65.20) | 0.7956 (Z = 0.2590) |
| C-reactive protein (mg/L) | ≤5 (≤5 - 10) | 5.5 (≤5 - 14.5) | 0.5667 (Z = -0.5729) |
| Procalcitonin (ng/ml) | 0.16 (0.08 - 0.44) | 0.29 (0.14 - 0.94) | 0.1946 (Z = -1.2971) |
|
| |||
| Numbers of hypervirulence genes | 5 (3.5 - 5) | 2 (1.75 - 2) | <.0001* (Z = 5.4348) |
| Hypermucoviscosity (n [%] | 18 (66.7) | 16 (28.6) | 0.0009* (χ2 = 10.9319) |
| Grade of serum resistance | 5 (5 - 6) | 5 (4 - 5) | 0.0013* (Z = 3.2113) |
| Siderophore units (%) | 26.0 (6.9 - 36.2) | 20.5 (3.6 - 28.4) | 0.1258 (Z = 1.5310) |
| 24-hour lethality of Galleria mellonella infection (%) | 60 (50 - 80) | 15 (10 - 30) | <.0001* (Z = 6.9503) |
|
| |||
| Carbapenemase-producing | 3 (11.1) | 27 (48.2) | 0.0010* (χ2 = 10.8656) |
| MDR | 7 (25.9) | 37 (66.1) | 0.0006* (χ2 = 11.7865) |
|
| |||
| Community acquired | 7 (25.9) | 5 (8.9) | 0.0136* (χ2 = 8.5952) |
| Healthcare associated | 10 (37.0) | 12 (21.4) | |
| Hospital acquired | 10 (37.0) | 39 (69.6) | |
|
| |||
| K1-ST23 | 4 (14.8) | 2 (3.6) | 0.0749 (χ2 = 3.1718) |
| K2-ST25 | 3 (11.1) | 3 (5.4) | 0.3575 (χ2 = 0.8467) |
| KL47-ST11 | 2 (7.4) | 24 (42.9) | 0.0011* (χ2 = 10.6416) |
| K1 and K2 | 14 (51.9) | 6 (10.7) | <.0001* (χ2 = 16.8553) |
|
| |||
| Severe pneumonia | 6 (22.2) | 7 (12.5) | 0.4126 (χ2 = 0.6714) |
| 30-day crude mortality | 1 (3.7) | 1 (1.8) | 0.5475 |
Test statistics are in brackets, P < 0.05 (*).
Values are shown as median (interquartile range) or No. (%) of cases; Inflammatory indicator data were examined on the same day or within two days of examination for K. pneumoniae pathogens.
Siderophore units were defined as [(Ar – As)/Ar] × 100 = X%.
Figure 3Verification of virulence phenotypes in murine sepsis model using selected hvKp (n = 6) and hgKp-Lv (n = 5) isolates with high-risk clones. (A) Mouse survival curves for NTUH-K2044 (hypervirulence control), hvKp isolates (K1-ST23 2020K105, K2-ST25 2019K134, K2-ST25 2020K14, K2-ST86 2019K71, K2-ST86 2019K136, and K16-ST660 2020K202), hgKp-Lv isolates (K2-ST25 2020K36, K16-ST660 2020K102, KL47-ST690 2020K201, KL47-ST11 2020K74, and wzi568-ST2355 2020K160), and cKp (low virulence control). The log-rank (Mantel–Cox) test was performed to assess the indicated curves. A significant difference (χ2 = 6.9078, P = 0.0086) was observed between the hvKp and hgKp-Lv groups. (B) Areas of bleeding in the alveolar space in infected mice. A significant difference (t = 2.33, P = 0.0446) was observed between the hvKp and hgKp-Lv groups, according to independent-samples t-test analysis. P < 0.05 (*). (C) Histological changes in lungs of infected mice. From left to right, images show mouse lungs infected with NTUH-K2044, hvKp 2020K105, hgKp-Lv 2020K36, and cKp, respectively.
Figure 4Risk ratio of hypervirulence genes in virulence-associated phenotypes. Risk ratios (95% confidence interval [95% CI]) and P values are given for pertinent results. P < 0.05 (*).
Figure 5Clinical manifestations of hvKp infection in children. (A) Infection setting of hvKp. CA, community-acquired infection; HC, healthcare-associated infection; HA, hospital-acquired infection. (B) Outcomes and associated infectious diseases in children with hvKp infection. Outcomes were assessed in terms of prognosis and recurrence during follow-up. (C) Comparison of clinical features between hvKp infections and hgKp-Lv infections. Odds ratios (OR) and P-values are shown for relevant results. P < 0.05 (*) and P < 0.001 (***).